Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

Overview

This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Full Title of Study: “Focal Adhesion Kinase Expression in Pediatric Renal Tumors”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 1, 2012

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether focal adhesion kinase (FAK) is expressed and if FAK is phosphorylated in pediatric renal tumors. OUTLINE: Archived tumor tissue samples are analyzed for FAK expression by immunohistochemistry (IHC). IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Interventions

  • Other: Laboratory Biomarker Analysis
    • Correlative studies

Arms, Groups and Cohorts

  • Basic science (FAK expression)
    • Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Clinical Trial Outcome Measures

Primary Measures

  • FAK expression in pediatric renal tumors
    • Time Frame: Baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Formalin-fixed, paraffin-embedded tissue samples from patients diagnosed with the following renal tumors: – Anaplastic Wilms tumor – Malignant rhabdoid tumor of the kidney – Clear cell sarcoma of the kidney – Mesoblastic nephroma

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Oncology Group
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Elizabeth Beierle, Principal Investigator, Children’s Oncology Group

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.